Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

194.30USD
17 Aug 2017
Change (% chg)

$0.15 (+0.08%)
Prev Close
$194.15
Open
$193.59
Day's High
$195.80
Day's Low
$193.59
Volume
23,208
Avg. Vol
371,242
52-wk High
$199.89
52-wk Low
$119.37

Latest Key Developments (Source: Significant Developments)

Illumina Q2 earnings per share $0.87
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Illumina Inc :Illumina reports strong financial results for second quarter of fiscal year 2017.Q2 non-GAAP earnings per share $0.82.Q2 GAAP earnings per share $0.87.Q2 revenue $662 million versus I/B/E/S view $642.4 million.Q2 earnings per share view $0.69 -- Thomson Reuters I/B/E/S.Illumina Inc says for fiscal 2017, company has updated its projections to approximately 12% revenue growth.Illumina Inc says for fy 2017 gaap earnings per diluted share attributable to illumina stockholders is forecasted to be $5.36 to $5.46.Illumina Inc says expects FY 2017 non-GAAP earnings per diluted share attributable to illumina stockholders of $3.60 to $3.70.Fy2017 earnings per share view $3.63, revenue view $2.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Inno-Gene says units reach agreement with Illumina over patent dispute
Monday, 26 Jun 2017 02:54am EDT 

June 26 (Reuters) - INNO-GENE SA ::SAID ON FRIDAY THAT ITS UNITS, CENTRUM BADAN DNA SP. Z O.O AND MEDGENETIX SP. Z O.O., REACHED SETTLEMENT WITH THE COMPANY ILLUMINA INC. <<>> CONCERNING VIOLATION OF INTELLECTUAL PROPERTY OF ITS PATENT.SAID ITS UNITS AFFIRMED VALIDITY OF ILLUMINA INC. PATENT AND ILLUMINA INC. WILL WITHDRAW THE LAWSUIT.  Full Article

HTG Molecular amends, restates IVD test development, component supply agreement with Illumina
Monday, 5 Jun 2017 08:00am EDT 

June 5 (Reuters) - HTG Molecular Diagnostics Inc ::Amended and restated its IVD test development and component supply agreement with Illumina.HTG Molecular Diagnostics - agreement extends term, increases number of in-vitro diagnostic test kits that may be developed with Illumina sequencing technology.  Full Article

HTG Molecular Diagnostics says ‍entered amended and restated development and component supply agreement with illumina
Friday, 2 Jun 2017 06:03pm EDT 

June 2 (Reuters) - HTG Molecular Diagnostics Inc ::HTG Molecular Diagnostics - ‍entered amended and restated development and component supply agreement with illumina, inc effective may 31 - sec filing​.HTG Molecular Diagnostics - ‍co required to pay illumina up to $0.6 million upon achievement of specified regulatory milestones relating to ivd test kits​.HTG Molecular Diagnostics- agreed to pay illumina single digit percent royalty on net sales of ivd test kits co commercializes pursuant to restated deal ‍​.HTG Molecular-‍filed amendment to prospectus supplement to increase amount of stock that may be offered in atm offering under sales deal to $40 million.  Full Article

Illumina reports Q1 GAAP earnings per share $2.52
Tuesday, 25 Apr 2017 04:05pm EDT 

April 25 (Reuters) - Illumina Inc :Illumina reports financial results for first quarter of fiscal year 2017.Q1 non-GAAP earnings per share $0.64.Q1 GAAP earnings per share $2.52.Q1 revenue $598 million versus I/B/E/S view $589.8 million.Q1 earnings per share view $0.64 -- Thomson Reuters I/B/E/S.Sees Q2 revenue up about 7 percent.Illumina inc - for fiscal 2017, company is projecting 10% to 12% revenue growth.Illumina Inc - for fiscal 2017, sees gaap earnings per diluted share attributable to illumina stockholders of $5.26 to $5.36.Sees 2017 non-GAAP earnings per diluted share attributable to illumina stockholders of $3.60 to $3.70.Sees Q2 GAAP earnings per diluted share attributable to illumina stockholders of $0.56 to $0.61.Sees Q2 non-GAAP earnings per diluted share attributable to illumina stockholders of $0.65 to $0.70.Q2 earnings per share view $0.87, revenue view $642.5 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.65, revenue view $2.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Illumina CEO Francis Desouza's FY 2016 total compensation was $8.4 mln - SEC Filing
Thursday, 30 Mar 2017 05:32pm EDT 

Illumina Inc : CEO Francis A. Desouza's FY 2016 total compensation was $8.4 million versus $5.4 million in FY 2015 - SEC Filing .Executive chairman Jay Flatley's FY 2016 total compensation was $3.0 million versus $9.2 million in FY 2015.  Full Article

Illumina says board increased size of board from 10 to 11 members
Tuesday, 21 Feb 2017 01:42pm EST 

Illumina Inc :On February 18, 2017, board increased size of board from ten to 11 members and elected John Thompson to board - SEC filing.  Full Article

Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017
Monday, 13 Feb 2017 07:50am EST 

Illumina Inc : Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing . Illumina Inc- Novaseq 5000 system and S3 flow cells are expected to be available for shipment in early 2018 - SEC filing . Illumina Inc- Novaseq 6000 system and S2 flow cells remain on track for shipment late in Q1 of this year - SEC filing Source: (http://bit.ly/2kKESiN) Further company coverage: [ILMN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Illumina Q4 non-gaap earnings per share $0.85
Tuesday, 31 Jan 2017 04:05pm EST 

Illumina Inc : Illumina reports full financial results for fourth quarter and fiscal year 2016 . Q4 non-gaap earnings per share $0.85 . Q4 gaap earnings per share $0.84 . Q4 earnings per share view $0.82 -- Thomson Reuters I/B/E/S . Sees FY 2017 non-gaap earnings per share $3.60 to $3.70 . Sees q1 gaap earnings per share $0.51 to $0.56 . Sees FY 2017 revenue up 10 to 12 percent . Sees q1 revenue $580 million to $595 million . Q4 revenue $619 million versus I/B/E/S view $616.4 million . Q1 earnings per share view $0.80, revenue view $618.6 million -- Thomson Reuters I/B/E/S . Fy2017 earnings per share view $3.65, revenue view $2.65 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 gaap earnings per share $3.25 to $3.35 .Illumina Inc - sees q1 non-gaap earnings per diluted share attributable to illumina stockholders of $0.60 to $0.65.  Full Article

Illumina appoints Sam Samad as senior VP and CFO
Wednesday, 7 Dec 2016 06:30am EST 

Illumina Inc: Illumina extends management team, appoints Sam A. Samad as senior vice president and chief financial officer .Sam A. Samad will join company on January 6, 2017.  Full Article

'Liquid biopsy' spots early-stage cancers in blood: U.S. study

CHICAGO A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."